Aimmune Therapeutics, Inc. announced the appointment of Jeffrey H. Knapp as Chief Operating Officer. Mr. Knapp brings a nearly 30-year track record of achievement in both large pharmaceutical and small biotechnology companies, including deep commercial experience and first-product launches. Mr. Knapp will join Aimmune on or about February 1, 2016.

Over his career, Mr. Knapp has led strategy and execution for multiple product launches across several therapeutic areas. Prior to Aimmune, Mr. Knapp was Chief Operating Officer at Adamas Pharmaceuticals, which he joined as Chief Commercial Officer in early 2014.